{Click on Image to Enlarge}
__
By Catalin Ghita, tramclub.org, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=8459457
Source:
____
Saturday, June 20, 2026
History of Mass Transportation: The Class 87 Diesel Shunter of the Romanian Railways
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Coronavirus Disease Research #References (AMEDEO, June 20 '26)
- SAFAVYNIA SA, Shanker A, Wang J, Choi JM, et al
Neurophysiological correlates of delayed recovery of consciousness in a critically ill patient with COVID-19 with repeated cardiac arrest.
Br J Anaesth. 2026 Jun 17:S0007-0912(26)00360-0. doi: 10.1016/j.bja.2026.
PubMed - KARANFIL O, Gullu D, Birinci S, Bayram S, et al
Crimean-Congo Hemorrhagic Fever in Turkiye, 2017-2024: Evolving Epidemiology and Implications for Surveillance.
Int J Infect Dis. 2026 Jun 18:108898. doi: 10.1016/j.ijid.2026.108898.
PubMed Abstract available - CHENG A, Meng L, Wang J, Liu L, et al
Post-Pandemic Forecasting of Pediatric Acute Respiratory Infections with Deep Learning: A Multi-Pathogen, Multi-Time-Horizon Study.
Int J Infect Dis. 2026 Jun 17:108889. doi: 10.1016/j.ijid.2026.108889.
PubMed Abstract available - LAUNAY O, Ansellem O, Dashraath P, Loubet P, et al
PREGNANT WOMEN COVID-19 IMMUNISATION IN 2026: EVIDENCE, UNCERTAINTY AND PRIORITIES.
Int J Infect Dis. 2026 Jun 13:108886. doi: 10.1016/j.ijid.2026.108886.
PubMed Abstract available - KONG M, Gao HX, Song XD, Yang GJ, et al
Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.
J Infect. 2026 Jun 18:106799. doi: 10.1016/j.jinf.2026.106799.
PubMed Abstract available - DONG S, Li M, Huo D, Zhao H, et al
Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.
J Infect. 2026;93:106795.
PubMed Abstract available - DINC HO, Uysal HK, Can G, Budak B, et al
Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.
J Med Virol. 2026;98:e71026.
PubMed Abstract available - GUPTA S, Chaudhary A, Bhatnagar S
SARS-CoV-2 Evolution and Its Implications for RT-PCR Diagnostic Performance.
J Med Virol. 2026;98:e71023.
PubMed Abstract available - MENG L, Cheng A, Tang D, Huang X, et al
Molecular Epidemiology, Viral Load and Clinical Severity of Human Adenovirus-Associated Respiratory Infections in Hospitalized Children in Shanghai, 2021-2023.
J Med Virol. 2026;98:e71011.
PubMed Abstract available - CHANG S, Shin J, Park S, Park H, et al
Limited Cross-Neutralization of Emerging SARS-CoV-2 BA.3.2.2 After LP.8.1-Updated Vaccination.
J Med Virol. 2026;98:e71025.
PubMed Abstract available
Correction to "Preconception COVID-19 Vaccination Reprograms Fetal Metabolism to Accelerate Intrauterine Recovery and Suppress Persistent Metabolic Memory".
J Med Virol. 2026;98:e71017.
PubMed- MARWAHA A, Alam B, Akbari AR
Reviewing the Use of Oral Melatonin in Critically Ill Covid 19 Patients.
J Med Virol. 2026;98:e71021.
PubMed - ZENG H, Shi Y, Zhong Q, Tang R, et al
RIG-I-dependent sensing of PEDV shapes epithelial antiviral immunity in the intestinal mucosa.
J Virol. 2026 Jun 16:e0048326. doi: 10.1128/jvi.00483.
PubMed Abstract available - ABUBAKAR I, Tellez D, Aldridge RW, Altare C, et al
The UCL-Lancet Commission on Migration and Health: review of the state of progress.
Lancet. 2026;407:2554-2576.
PubMed Abstract available - SASIENI P, Falcaro M
Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
PubMed Abstract available
Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
Lancet. 2026 Jun 17:S0140-6736(26)00761-0. doi: 10.1016/S0140-6736(26)00761.
PubMed Abstract available
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Jun. 20 '26)
- KOUTOURATSAS T, Dammad T, Mylonakis E
In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.
Ann Intern Med. 2026 Jun 2. doi: 10.7326/ANNALS-26-01878.
PubMed Abstract available - COTTON D
"Never More Than 15 Feet From the Respirator": Housestaff Research During the 1955 Boston Polio Epidemic.
Ann Intern Med. 2026 Apr 28. doi: 10.7326/ANNALS-25-05440.
PubMed Abstract available - AHMADY A, Mickleburgh I, Bryant N, Carnell GW, et al
Enhanced virucidal activity of quaternary ammonium compound-thymol combinations: influence of mucin and mucoadhesive polymers.
Arch Virol. 2026;171:215.
PubMed Abstract available - SANYAL D, Chaubey B
SARS-CoV-2 3CL protease interaction with host factors - identifying novel drug targets.
Arch Virol. 2026;171:202.
PubMed Abstract available - GRUENDL M, Campos LN, Dey T, Nkurunziza T, et al
Epidemiology of children and adolescents undergoing surgery at Mexican public hospitals: a retrospective registry-based analysis from 2010 to 2022.
BMC Pediatr. 2026;26:553.
PubMed Abstract available - KARADENIZ HB, Zilan S, Yazici MB, Derelioglu SS, et al
COVID-19 and first permanent molar extractions in children: a comparative retrospective study.
BMC Pediatr. 2026;26:567.
PubMed Abstract available - UEKI H, Tomita Y, Duong C, Mitake H, et al
A CRISPR knockout mouse library for functional genomics in influenza research.
Cell. 2026 Jun 16:S0092-8674(26)00591-X. doi: 10.1016/j.cell.2026.
PubMed Abstract available - NEMCOVA B, Goldstein IH, Sebastian J, Minin VM, et al
Unjustified Poisson assumptions lead to overconfident estimates of the effective reproductive number.
Epidemiol Infect. 2026;154:e79.
PubMed Abstract available - MOSCROP A, Dorling D, Cole T
'British children are not shrinking', but child height is increasing for the wrong reasons: trends and inequalities in child measurement programme data for England, Scotland and Wales.
J Epidemiol Community Health. 2026;80:534-540.
PubMed Abstract available - NABIL NM, Tawakol MM, Hagag N, Eid S, et al
Molecular surveillance and predictive risk modelling of avian influenza virus in wild birds in Egypt.
J Gen Virol. 2026;107:002278.
PubMed Abstract available - LU L, Long Z, Chen F, Li Z, et al
Global Disability-Adjusted Life Years Burden of Lower Respiratory Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.
J Infect. 2026 May 25:106768. doi: 10.1016/j.jinf.2026.106768.
PubMed Abstract available - NURMI V, Hedman L, Vapalahti K, Hepojoki J, et al
Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.
J Infect Dis. 2026;233:e1374-e1385.
PubMed Abstract available - CASERTA MT, Mariani TJ, Walsh EE, Gill SR, et al
Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus.
J Infect Dis. 2026;233:1027-1035.
PubMed Abstract available - LIN DY, Mischell MA, Zhang X, Mollan KR, et al
Incidence and Severity of Postacute Sequelae of SARS-CoV-2 Infection in the Omicron Era: A Prospective Cohort Study.
J Infect Dis. 2026;233:1063-1068.
PubMed Abstract available - LV C, Wang S, Song M, Wu J, et al
The nicotinamide phosphoribosyltransferase inhibitor FK866 restricts influenza A virus replication by perturbing viral polymerase activity.
J Virol. 2026 Jun 15:e0059126. doi: 10.1128/jvi.00591.
PubMed Abstract available - NGUYEN X-D, Le BT, Bleich J, Espada C, et al
Environmental temperature and relative humidity shape post-emission aerosol fate and airborne influenza transmission.
J Virol. 2026 Jun 15:e0063426. doi: 10.1128/jvi.00634.
PubMed Abstract available - HUI X, Tian X, Xue C, Ding S, et al
KCMF1-mediated influenza A virus PB1 ubiquitination at K653 regulates viral replication.
J Virol. 2026 Jun 15:e0048126. doi: 10.1128/jvi.00481.
PubMed Abstract available - ABUBAKAR I, Tellez D, Aldridge RW, Altare C, et al
The UCL-Lancet Commission on Migration and Health: review of the state of progress.
Lancet. 2026;407:2554-2576.
PubMed Abstract available - MCKINLEY TJ, Williamson DB, Xiong X, Salter JM, et al
On real-time calibrated prediction for complex model-based decision support in pandemics: Part 2.
PLoS Comput Biol. 2026;22:e1014299.
PubMed Abstract available - SHEFFIELD T, Bruneau RC, Won S, Sale KL, et al
Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern.
PLoS Comput Biol. 2026;22:e1014394.
PubMed Abstract available - HIRABAYASHI K, Lorman V, Wuller S, Aragon LV, et al
Evaluation of steroids for acute COVID in the prevention of long COVID in children: An EHR and pediatric cohort study from the RECOVER Initiative.
PLoS One. 2026;21:e0350888.
PubMed Abstract available - ALENAZI S, Mohanty J, Srinivasan M, Samontaray DP, et al
"The impact of COVID-19 on employee productivity and the future of remote work".
PLoS One. 2026;21:e0351968.
PubMed Abstract available - HEUDORF U, Kowall B
All?cause excess mortality in Germany peaked during the late?2022 influenza period, exceeding peaks during SARS?CoV?2 waves (2020-2023).
PLoS One. 2026;21:e0335982.
PubMed Abstract available - KIM SJ, Kim J
Symptom profiles and health-related quality of life in Korean adults with post-acute sequelae of SARS-CoV-2 infection (PASC): A latent profile analysis.
PLoS One. 2026;21:e0351506.
PubMed Abstract available - HOLDSWORTH L, Jackson M, Piggin L, Kambulandu M, et al
The experiences of doctors in Lesotho during the COVID-19 pandemic: A qualitative study.
PLoS One. 2026;21:e0350935.
PubMed Abstract available - HELMSDAL G, Kristiansen MF, Gaard EK, Eysturoy BJ, et al
Persistent symptoms, cognitive impairment, and clinical predictors of long COVID one year after Omicron infection: A clinical case-control study from the Faroe Islands.
PLoS One. 2026;21:e0351564.
PubMed Abstract available - KEHL-FLOBERG K, Freisberg E, Pop-Vicas A, Gangnon R, et al
Long COVID risk by pre-infection symptoms and functional status: A retrospective cohort study of data from the All of Us Research Program.
PLoS One. 2026;21:e0330793.
PubMed Abstract available - BHAN PC, Schroeder M, Turchet D, Wen J, et al
The time sensitivity of aspirational interventions: Evidence from a role-modeling RCT.
PLoS One. 2026;21:e0350832.
PubMed Abstract available - WHITE DL, NonoDjotsa ABS, Ahmed ST, Boyle SH, et al
Association between deployment and Gulf War Illness and adverse COVID outcomes in a nationwide cohort of 1990-1991 Gulf Era war veterans in the VA's Million Veteran Program.
PLoS One. 2026;21:e0348594.
PubMed Abstract available - REID-WESTOBY C, Duku E, Gaskin A, Janus M, et al
Chronic absenteeism in Canadian kindergarten classes, pre- and post-COVID-19, and its association with concurrent developmental vulnerability.
PLoS One. 2026;21:e0345192.
PubMed Abstract available - YANG SD, Qi F, Colwill K, Gingras AC, et al
SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations.
PLoS One. 2026;21:e0327692.
PubMed Abstract available - GEBRETEKLE GB, Lan M, Xi M, Ximenes R, et al
Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis.
PLoS One. 2026;21:e0351183.
PubMed Abstract available - NISSLEY-TSIOPINIS J, Fleming PF, Chan W, Langberg JM, et al
Cluster-randomized trial of Homework, Organization, and Planning Skills program compared to treatment as usual/waitlist for youth ages 11-14: Study protocol for conceptual replication.
PLoS One. 2026;21:e0343894.
PubMed Abstract available - EL-ATFY ES, Gadallah AM, Alsahangiti AM, Balogun OS, et al
Laplace Transform-Based Nonparametric Test of Exponentiality against DMRL class with preservation under the Homogeneous Poisson Shock Model and applications in survival analysis and reliability.
PLoS One. 2026;21:e0349216.
PubMed Abstract available - FATIMA Z, Surette MD, Marttala S, Leto D, et al
Microbiome analysis of bronchoalveolar lavage (BAL) specimens from immunocompromised patients with pneumonia compared to those from healthy volunteers.
PLoS One. 2026;21:e0351562.
PubMed Abstract available - TRAIN A, Vemuri KK, Coderre-Ball A, Silva-Valencia J, et al
Prescription patterns of inhaler medications from 2017 to 2023: A retrospective study using Ontario administrative healthcare data.
PLoS One. 2026;21:e0348119.
PubMed Abstract available - VASUDEV C, Mishra S, Rathi A, Fledderjohann J, et al
Diverse coping strategies for food insecurity: A qualitative study of economically precarious households in India in the context of COVID-19.
PLoS One. 2026;21:e0350020.
PubMed Abstract available - KHAM-KJING N, Kawila R, Tariyo P, Puapun K, et al
Etiology of severe acute respiratory infections among adults in northern Thailand using multiplex PCR: A post-COVID-19 surveillance study (2023-2024).
PLoS One. 2026;21:e0350198.
PubMed Abstract available - GODBOLE N, Choi S, Shim K, Liu Y, et al
A study protocol for mixed-methods evaluation of the structure, design, and availability of medical student wellbeing programs.
PLoS One. 2026;21:e0351759.
PubMed Abstract available - ROHAN H, Bochner AF, Brown L, Ortiz EM, et al
COVID-19 alert level systems-Lessons learnt for future public health emergencies: A qualitative study.
PLoS One. 2026;21:e0351209.
PubMed Abstract available - LEVITT M, Marten B, Oren G, Ioannidis JPA, et al
Reclassification and weighting of multiple causes of death: US death certificates 2003-2023.
Proc Natl Acad Sci U S A. 2026;123:e2604493123.
PubMed Abstract available - MALHOTRA G, Bilguche A, Eades O, Loftus MJ, et al
Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.
Vaccine. 2026;86:128735.
PubMed Abstract available - KATANA EB, Kiiza D, Odongpiny EAL, Simbwa BN, et al
Willingness to receive Ebola vaccines among pregnant and lactating women in Kampala, Uganda: insights from a post-outbreak cross-sectional study.
Vaccine. 2026;86:128737.
PubMed Abstract available - GIANNINI F, Hogan AB, Blyth CC, Glass K, et al
Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia.
Vaccine. 2026;86:128731.
PubMed Abstract available - DVORKIN J, Pico M, Guinazu G, Crespi MS, et al
Residual burden of severe RSV disease in infants during the first season of maternal RSVpreF immunization in Argentina: A hospital-based, multicentre, retrospective cohort study.
Vaccine. 2026;87:128773.
PubMed Abstract available - QI X, Smolders C
From COVAX deliveries to vaccination uptake in LMICs: a monthly panel analysis.
Vaccine. 2026;86:128763.
PubMed Abstract available - EIDEN AL, Zheng Y, Wang D, Frew PM, et al
Changes in attitudes and beliefs about childhood vaccination among parents in the United States: A repeat cross-sectional survey before and after the COVID-19 pandemic.
Vaccine. 2026;87:128760.
PubMed Abstract available - DELLA CIOPPA G, Sahai N, Dodeur V, Dutton JL, et al
Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo-
Vaccine. 2026;87:128772.
PubMed Abstract available - MOROS A, Deulofeu M, Ribo M, Bosch-Rue E, et al
Multiple monovalent COVID-19 PHH-1V vaccine adaptations elicit homologous and cross-neutralizing antibody responses in mice.
Vaccine. 2026;87:128781.
PubMed Abstract available - SPILA-ALEGIANI S, Massari M, Cutillo M, Menniti-Ippolito F, et al
Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study.
Vaccine. 2026;88:128806.
PubMed Abstract available - BUSH C, Desai S, Wang H, Hsu WC, et al
Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023.
Vaccine. 2026;88:128821.
PubMed Abstract available - CHRISTOU-ERGOS M, Sabahelzain MM, Bolsewicz KT, Kaufman J, et al
Australian adults' views on influenza vaccination: Implications for communication and service quality from a qualitative study.
Vaccine. 2026;88:128846.
PubMed Abstract available - LE MH, Tran ND, Nguyen TTT, Phan TTN, et al
Willingness to pay for influenza vaccination among the elderly in Vietnam: A triple-bounded dichotomous choice analysis of economic and behavioral determinants.
Vaccine. 2026;88:128852.
PubMed Abstract available - VALENZUELA-FUENZALIDA JJ, Velarezco LM, Silva V, Delgado F, et al
Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
Virus Res. 2026 May 20:199748. doi: 10.1016/j.virusres.2026.199748.
PubMed Abstract available - MANZOOR M, Banday MS, Para BA, Rani VI, et al
Mental health strain due to COVID-19: Psychological distress and somatic symptoms among health care workers and the general population in Kashmir, India.
Virus Res. 2026;369:199753.
PubMed Abstract available - TRAMONTOZZI C, Riccio A, La Frazia S, Svicher V, et al
Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.
Virus Res. 2026;369:199743.
PubMed Abstract available
Ann Intern Med
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Friday, June 19, 2026
#Genomic #epidemiology of two #travel-associated #pediatric #measles viruses within the B3 Lineage
Highlights
• The Children’s Hospital of Philadelphia (CHOP) detected a B3 MeV case in 2023 and in 2025.
• Whole-genome amplification of the two CHOP B3 MeV isolates was performed.
• The CHOP genomes were assessed with a global dataset of all 168 National Center for Biotechnology Information B3 MeV near-full length genomes from 2005-2025.
• The CHOP isolates form a clade with 39 other isolates from four countries, 36 of which cluster with a 15 single nucleotide polymorphism cutoff.
• The CHOP clade diverged in 2019, contains the most recently emerged B3 nodes, and shares a private mutation in the phosphoprotein at a codon undergoing positive selection.
Abstract
Background
Children’s Hospital of Philadelphia (CHOP) identified a MeV case in late 2023 and also early 2025, both of which were associated with international travel. Of the 24 MeV genotypes, the B3 and D8 lineages have been the most prevalent globally since 2021. Initial genotyping indicated that the two CHOP isolates belong to the B3 lineage.
Objectives
To inform MeV molecular surveillance, we conducted a genomic epidemiology analysis to situate the CHOP strains within the global genetic landscape of past and present MeV B3 cases.
Study design
We performed whole-genome amplification, genome assembly, and phylogenomics of our two MeV cases. These strains were then analyzed alongside all 168 National Center for Biotechnology Information near-full length MeV B3 genomes using population and evolutionary genetic approaches. This dataset includes strains isolated from 13 countries between 2005 and 2025.
Results
The two CHOP strains form a monophyletic group with 39 other isolates from four countries; 36 clade members form a discrete network connected by a 15 single nucleotide polymorphism (SNP) cutoff. The CHOP clade shares a Q45H phosphoprotein mutation at a codon undergoing diversifying selection, as with a H593R hemagglutinin mutation carried by the 2025 CHOP strain. The CHOP clade likely diverged in 2019 and has a median root-to-tip distance of 0.020 compared to 0.017 for the other B3 strains, consistent with this clade encompassing the most recently divergent nodes.
Conclusions
Our work places the CHOP MeV cases within a diversifying and emergent global clade of the dominating B3 lineage that is a future risk due to ongoing B3 MeV transmission.
Source:
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Beyond the cruise #ship: #Andes #hantavirus and the neglected #onehealth dimensions of global #outbreak #preparedness
{Summary}
The ongoing multi-country outbreak of Andes hantavirus linked to an expedition cruise travel has drawn global public health attention. The outbreak was reported to the World Health Organization on 02 May 2026 after a cluster of severe respiratory illness occurred among passengers and crew aboard the MV Hondius, which travelled across remote regions of the South Atlantic following departure from Ushuaia, Argentina. As of 18 May 2026, the European Centre for Disease Prevention and Control (ECDC) reported 12 cases, including nine confirmed, two probable, and one inconclusive case, as well as three deaths linked to the outbreak. While response efforts have appropriately focused on case detection, isolation, contact monitoring, and clinical management, the event highlights broader gaps in how emerging zoonotic threats are managed globally. Rather than viewing this solely as a cruise-associated outbreak, it should also be understood as a One Health warning signal emerging at the intersection of rodent ecology, environmental and climatic change, expedition tourism, and global human mobility.
(...)
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Ebola disease caused by #Bundibugyo virus, #DRC & #Uganda (WHO D.O.N., June 19 '26): 896 confirmed cases and 232 deaths in DRC; No New Cases in Uganda
Situation at a glance
The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo continues to evolve rapidly, with sustained transmission and increasing numbers of reported cases.
As of 17 June, a cumulative of 896 confirmed cases, including 232 deaths, have been reported from the Democratic Republic of the Congo.
As of 18 June, Uganda has reported 19 confirmed cases including two deaths, as well as one probable case who has died.
In Uganda, the outbreak remains epidemiologically linked to transmission originating in the Democratic Republic of the Congo, with evidence of both imported infections and secondary transmission among contacts and healthcare workers.
Uganda has not reported any new cases since 5 June 2026.
National authorities in the two affected countries, in collaboration with WHO and partners, are implementing an extensive set of response measures.
A regional preparedness and prioritization framework continues to guide readiness activities across the African Region.
Description of the situation
Since the last Disease Outbreak News was published on 13 June 2026, the number of confirmed cases and deaths have increased rapidly in the Democratic Republic of the Congo.
In total, 915 confirmed cases; 896 from the Democratic Republic of the Congo and 19 from Uganda; and 234 deaths including two from Uganda, have been reported.
At least 88 patients have recovered from the disease; 78 patients from the Democratic Republic of the Congo and 10 patients from Uganda.
(...)
Democratic Republic of the Congo
Since 13 June when the last Disease Outbreak News was published, an additional 220 confirmed cases, including 96 confirmed deaths, have been reported from the Democratic Republic of the Congo.
The increase is in part due to the scale up of testing and diagnostic capacities, enabling testing of the backlog of previously collected samples.
As of 17 June 2026, a total of 896 confirmed cases including 232 deaths (case fatality ratio [CFR] 26%) have been reported from the Democratic Republic of Congo.
The reported CFR is likely an underestimation, as many deaths that occurred before the outbreak declaration remain under investigation.
So far, 78 patients have recovered.
Cases have been reported from 33 health zones (HZ) from Ituri (21/36 HZ), North Kivu (11/35 HZ) and South Kivu provinces (1/34 HZ)[1].
The outbreak remains concentrated in Ituri Province, which accounts for 91.1% (817) of the confirmed cases with a CFR of 22.7% (186/817).
The highest number of confirmed cases in Ituri Province are reported from Bunia (247 cases), Rwampara (195 cases), Mongbwalu (189 cases), and Nyankunde (68 cases) health zones.
So far, the epicentre of the outbreak remains Ituri, with new confirmed cases reported from an additional four health zones as of 17 June.
However, the identification of cases in some of these newly reporting health zones may reflect previously undetected transmission rather than recent introduction of the virus.
Epidemiological investigations indicate that transmission had likely been occurring in some of these areas for several weeks before the first cases were confirmed and reported.
Of the total confirmed cases, 17 are awaiting distribution by health zone.
As of 17 June, 6367 contacts have been identified and are under follow-up across Ituri (4659), North Kivu (1628), and South Kivu (80) provinces.
Of these, 4525 contacts have been followed up, corresponding to follow-up rates of 70.8% in Ituri, 70.5% in North Kivu, and 100% in South Kivu.
The outbreak is unfolding in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations, often lacking access to basic services, including food, clean water, shelter, healthcare and protection which poses an increased risk to the populations living in overcrowded internally displaced camps.
These dynamics, combined with increasing security-related incidents affecting health facilities, have posed additional operational challenges in affected provinces, such as constrained access for response teams, disrupted surveillance and response activities, and heightened risk of undetected transmission.
These conditions underscore the need for response efforts to be led by local leaders and anchored in communities.
___
Figure 2: Number of confirmed cases (n = 896), in the Democratic Republic of the Congo, by date of reporting as of 17 June 2026
{Click on Image to Enlarge}
___
Figure 3: Number of deaths among confirmed cases (n = 232), in the Democratic Republic of the Congo, by date of reporting as of 17 June 2026
{Click on Image to Enlarge}
Uganda
The last confirmed case was reportedly identified on 5 June 2026.
As of 18 June 2026, a cumulative of 19 confirmed cases including two deaths in imported cases (reported on 15 May and 5 June), and one probable case who has died, have been reported.
Of the confirmed cases, 14 cases are imported and five are secondary transmission among contacts and health workers following cases imported from the Democratic Republic of the Congo.
The cases have been reported from two districts, Kampala and Wakiso, both part of the Kampala Metropolitan Area.
To date, there has been no documented community transmission in Uganda.
Exposure risks are associated with healthcare settings and cross-border movements.
Following case reclassification, the number of affected healthcare workers was revised from five to four.
In total 10 recoveries have been reported to date.
Of the 826 contacts listed as of 18 June, a total of 122 contacts are under active follow up and 694 contacts have completed their 21-day follow-up period.
___
Figure 4: Number of confirmed cases (n = 19), in Uganda by date of reporting as of 18 June 2026
{Click on Image to Enlarge}
Epidemiology
Bundibugyo virus disease (BVD) is a severe and often fatal form of Ebola disease caused by the Bundibugyo virus, one of the Orthoebolavirus species.
It is a zoonotic disease, with fruit bats suspected to be the natural reservoir.
Human infection is thought to occur through close contact with the blood or secretions of infected wildlife, such as bats or non-human primates, and it subsequently spreads from person to person through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or contaminated surfaces or items.
Transmission is particularly amplified in health-care settings when infection prevention and control (IPC) measures are inadequate, and during unsafe burial practices involving direct contact with the deceased.
The incubation period for BVD ranges from two to 21 days, and individuals are not infectious until symptom onset.
Early symptoms such as fever, fatigue, muscle pain, headache, and sore throat, are non-specific, which complicates clinical diagnosis and can delay detection.
These symptoms then progress to gastrointestinal symptoms, organ dysfunction, and in some cases haemorrhagic manifestations.
CFRs in the past two BVD outbreaks, reported in Uganda and in the Democratic Republic of the Congo in 2007 and 2012 were 30% and 50%, respectively.
Differentiating BVD from other endemic febrile illnesses such as malaria is challenging without laboratory confirmation using PCR or antigen/antibody-based assays.
Outbreak control relies on rapid case identification, isolation and care, contact tracing, safe burials, and strong community engagement, as no approved vaccines or specific treatments currently exist for BVD.
Public health response
Health authorities in the Democratic Republic of the Congo and Uganda, in collaboration with WHO and partners, are implementing extensive public health measures including implementing the continental response plan, engaging donors and mobilizing additional resources to address critical funding gaps and sustain response operations across affected and at-risk areas.
For further information about public health response actions by the respective Ministry of Health, WHO, and partners, please refer to the latest situation reports published by the WHO Regional Office for Africa Ebola Bundibugyo Virus Disease Outbreak Democratic Republic of the Congo | Uganda Weekly External Situation Report 5, Data as of 14 June 2026 | WHO | Regional Office for Africa
WHO risk assessment
On 6 June 2026, WHO reassessed the risk of the outbreak of BVD to incorporate newly available information and align with the WHO Temporary Recommendations.
The risk for countries sharing land borders with countries with documented Bundibugyo virus (BVDV) detection, currently the Democratic Republic of the Congo and Uganda, has been separated out from the risk for other countries in the African Region.
The risk in the Democratic Republic of the Congo remains assessed as very high due to ongoing transmission and the continued expansion of the outbreak into new health zones, increasing the potential for further national and regional spread.
The risk in Uganda is still assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor, historically affected by Ebola outbreaks, including Bundibugyo and Sudan virus disease outbreaks.
The risk for countries with land borders adjoining countries with documented BDBV detection is assessed as high due to sustained population mobility linked to cross-border trade and mining activities, variation in capacities and experience of BVD response, and variable levels of readiness.
The risk for the rest of the Africa region and at the global level is assessed as low.
For further information, please see the WHO Rapid Risk Assessment – Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo, Uganda and countries with land borders adjoining countries with documented BDBV detection v3.
WHO advice
WHO advises against any restriction of travel to, or trade with, the Democratic Republic of the Congo or Uganda based on the currently available information. WHO continues to closely monitor and, where necessary, verify travel and trade measures in relation to this event.
For further information on the considerations for implementing border health and international travel-related temporary recommendations, please see the relevant technical note issued on 26 May 2026.
The Temporary Recommendations issued to State Parties on 22 May 2026 underscore the importance of coordinated outbreak control, enhanced cross‑border collaboration, and sustained surveillance and preparedness to prevent further regional spread and ensure an effective public health response.
WHO has convened several technical advisory groups, including the Strategic Advisory Group of Experts on Immunization (SAGE) to assess candidate vaccines and therapeutics for BVD. Key recommendations made are available in the news release published on 28 May 2026.
(...)
Citable reference: World Health Organization (19 June 2026). Disease Outbreak News; Bundibugyo Virus Disease, Democratic Republic of the Congo and Uganda. Available at: https://www/who.int/emergencies/disease-outbreak/news/item/2026-DON608
[1] #Data source: Centre des opérations d'urgences de sante publique (COUSP-DRC)
Source:
Link: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON608
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Potent In Vitro #Antiviral Activity of 4'-Fluorouridine Against Diverse #Orthohantaviruses including #Andes Virus
Highlights:
• 4′-fluorouridine exhibits broad-spectrum activity against 16 orthohantaviruses.
• The compound inhibits hantavirus replication by targeting the viral polymerase.
• Efficacy is maintained in human endothelial and airway epithelial cells.
Abstract
Hantaviruses are emerging pathogens responsible for severe and often fatal diseases, including hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS), for which no FDA-approved antivirals currently exist. Using a Seoul virus minigenome system, we first confirmed that the ribonucleoside analog 4’-fluorouridine (EIDD-2749) effectively targets the hantavirus polymerase complex, inhibiting viral RNA transcription and replication. We subsequently evaluated its antiviral activity against a comprehensive panel of 16 hantaviruses representing both Old and New World lineages including both the Chilean and Argentinian strains of Andes virus. 4’-fluorouridine demonstrated potent, dose-dependent inhibition across all viruses tested, with EC50 values uniformly in the low- to sub-micromolar range. Collectively, these findings establish 4’-fluorouridine as a highly potent, pan-hantavirus inhibitor and a promising candidate for further preclinical development.
Source:
Link: https://www.sciencedirect.com/science/article/abs/pii/S0166354226001269?via%3Dihub
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Ebola #outbreak caused by #Bundibugyo virus: challenges and priorities for #epidemic preparedness and response
{Summary}
Since WHO declared the ongoing outbreak of Ebola virus disease caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense; BDBV) in DR Congo and Uganda a public health emergency of international concern and the Africa Centres for Disease Control and Prevention (Africa CDC) declared a public health emergency of continental security, the outbreak has continued to evolve rapidly. As of June 3, 2026, 344 laboratory-confirmed cases and 60 deaths had been reported in DR Congo, while Uganda had reported 15 confirmed cases and one death; cross-border transmission has prompted heightened preparedness and response measures across the region.1–3 The outbreak poses a substantial public health threat because diagnosis is often delayed by limited access to suitable point-of-care assays, and no licensed vaccine or approved virus-specific therapeutic currently exists for BDBV. Barriers to controlling the BDBV outbreak and priority response actions are summarised in the table.
(...)
Source:
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Single-dose #mRNA #vaccines against #Andes #hantavirus
{Summary}
The May, 2026, Andes virus outbreak on the Dutch cruise ship (MV Hondius) that departed from Argentina, where the lethal virus was first described, represents a transmission context unprecedented in the known epidemiology of the virus. The Andes virus is the only member of the Hantaviridae family capable of efficient person-to-person spread through close contact with respiratory secretions. The epidemic potential of the virus was demonstrated during the 2018–19 EpuyĂ©n outbreak in Argentina, where four waves of infection from a social gathering resulted in 34 confirmed cases and 11 deaths. Despite passengers on board MV Hondius having now returned to their home countries, there are currently 13 reported cases with three deaths. The dispersal of nearly 150 passengers and high-risk contacts across 23 countries, monitored under varying quarantine protocols, and a 42-day virus incubation window, presents a complicated and critical vulnerability for public health agencies. Contact tracing is ongoing as ambiguity surrounds secondary transmission cases before containment measures were established. There are no vaccines or preventive treatments currently approved by the US Food and Drug Administration or the European Medicines Agency. The travel-related outbreak and potential for sequential transmission events underscore the urgency for vaccine development.
(...)
Source:
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Mechanistic and #antigenic boundaries of #Henipavirus and Parahenipavirus #glycoproteins
Abstract
Henipaviruses, in the Paramyxoviridae family, includes the highly virulent Nipah virus that causes reoccurring outbreaks of deadly disease. Recent discoveries of Henipavirus-like species, including the zoonotic Langya virus, have revealed much higher antigenic diversity than currently characterized and prompted the reorganization of these viruses into the Henipavirus and Parahenipavirus genera. Here, to explore the limits of structural and antigenic variation in both genera, collectively referred to as HNVs, we construct an expanded, diverse panel of HNV fusion and attachment glycoproteins from non-redundant HNV strains that better reflect global HNV diversity. We express and purify the fusion protein ectodomains and the attachment protein head domains and study their biochemical and biophysical properties. We perform immunization experiments in mice, eliciting antibodies reactive to multiple HNV fusion proteins. Cryo-electron microscopy structures elucidate molecular determinants of differential pre-fusion state stability and higher order contacts. A crystal structure of the Gamak virus attachment head domain reveals an additional domain appended to the conserved 6-bladed, β-propeller fold. Taken together, these studies expand the known structural and antigenic limits of the HNVs, reveal cross-reactive epitopes within both genera and provide foundational data for the development of broadly reactive countermeasures.
Source:
Link: https://www.nature.com/articles/s41467-026-74212-8
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Thursday, June 18, 2026
The #risk of #global #Ebola virus #spread is low: #epidemiology of Ebola disease cases outside Africa, 1976 to May 2026
Abstract
Following the Bundibugyo virus disease outbreak reported in the Democratic Republic of the Congo in May 2026, we reviewed all known Ebola disease cases outside Africa and found that intercontinental transmission risk remains low. We identified 28 confirmed epidemic-linked cases outside Africa; only four involved travellers with latent infection whose symptoms were detected after border screening. Excluding medically evacuated cases, the crude overall risk since 2000 was 0.17 Ebola disease cases outside Africa per 1,000 reported cases in Africa.
Source:
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Andes virus #outbreak linked to expedition cruise #ship travel, multi-country #investigation and response, April to June 2026
Abstract
As at 18 June 2026, 13 cases (12 confirmed and one probable) of Andes orthohantavirus have been reported (case–fatality: 23%), linked to the Dutch-flagged expedition cruise ship MV Hondius. The event involved individuals from 23 nationalities and required medical evacuation, repatriation, coordinated international contact tracing, isolation, quarantine and clinical and laboratory testing follow-up. To date, all cases have been passengers (10/121; 8%) or crew members (3/61; 5%). Ongoing monitoring and investigations aim to clarify the source of the outbreak, identify risk factors and prevent further spread.
Source:
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Biodiversity and emerging infectious #threats: the microbial dark matter of Southwest #China
Abstract
Southwest China is a global biodiversity hotspot, and its complex and diverse ecosystems harbor vast amounts of “microbial dark matter.” This paper systematically examines the distribution characteristics of microbial dark matter in hosts such as arthropods, mammals, and birds, as well as in environments including soil, hot springs, and high-altitude lakes, with a particular focus on the cross-species transmissibility and pathogenic potential of emerging pathogens. Research indicates that new microbial species in the Southwest exhibit significant geographic concentration and host specificity: Yunnan Province is a core hotspot, while the Tibet Autonomous Region contributes a wealth of microbial resources due to its extreme environments, with arthropods and mammals accounting for the highest proportion of novel species. Regarding public health risks, eight novel pathogens with evidence of human infection have been identified, spanning the three major groups of viruses, bacteria, and parasites. The cross-species transmission potential of some pathogens (such as DPRV rhabdovirus, PPV arenaviridae, Luxi hantavirus, Banna virus and a novel Babesia species) has been confirmed through serological surveys or molecular testing. Deepening the exploration of microbial dark matter and risk early warning in this region will provide critical scientific support for public health safety monitoring.
Source:
Link: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1846062/full
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
#Surveillance of West Nile Virus {#WNV} #Human #Infections in #Europe, Weekly Report (ECDC, Jun. 18 '26): First two cases reported in #Italy
Epidemiological summary
Since the beginning of 2026, and as of 17 June, 2 countries in Europe reported 3 human cases of West Nile virus infection: Italy and North Macedonia.
The current report in Table 1 includes the number of probable and confirmed cases of WNV infections per NUTS region.
However, these figures are preliminary and should be interpreted with caution as they may be revised by the countries as more information becomes available.
Consequently, no totals are provided.
For further details on case numbers, please refer to the joint monthly report, which offers a more detailed analysis.
Please note: The table and map in this report contain countries and areas where human West Nile virus infection cases were reported to EpiPulse Cases.
Introduction
The European Centre for Disease Prevention and Control (ECDC) provides a weekly overview of human cases of West Nile virus (WNV) infection to support the competent authorities responsible for blood safety.
This overview can aid decisions on the deferral or testing of blood donors who may have been exposed to the virus, in accordance with Commission Directives 2004/33/EC and 2014/110/EU.
West Nile virus infection in humans is a notifiable disease at the EU level and cases are reported in accordance with the EU case definition.
The table and map in this report show the countries and areas where human cases of WNV infection have been reported to the European surveillance portal for infectious diseases (EpiPulse Cases).
More information on the occurrence of WNV infection among humans in Europe, as well as WNV outbreaks among equids and birds, is available in the joint monthly report produced by ECDC and the European Food Safety Authority (EFSA).
Here we present the weekly report as of 17 June 2026.
Overview of West Nile virus cases in EU/EEA and EU-neighbouring countries
Table 1. Countries and regions with locally acquired human cases of West Nile virus infections in 2026 as of 17 June.
[Country
° Affected Region
§ Newly Affected Region
* No. of Probable / Confirmed / Total Cases]
Italy
° Caserta
§ Yes
* 0 / 1 / 1
° Firenze
§ Yes
* 0 / 1 / 1
Macedonia
° Vardarski
§ No
* 0 / 1 / 1
(...)
Source:
Link: https://wnv-weekly.ecdc.europa.eu/
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Subscribe to:
Posts (Atom)
Most Popular Posts
-
{Summary} The May, 2026, Andes virus outbreak on the Dutch cruise ship (MV Hondius) that departed from Argentina , where the lethal virus ... -
{Summary} Since WHO declared the ongoing outbreak of Ebola virus disease caused by Bundibugyo virus (species Orthoebolavirus bundibugyoens... -
Public health guidance This table and accompanying algorithm provide guidance for EU/EEA public health authorities, decision-makers,...